This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance
by Zacks Equity Research
DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience and expanding diabetes care access.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL continues to gain from its robust product portfolio and strong segmental performance.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Veeva (VEEV) Moves 3.7% Higher: Will This Strength Last?
by Zacks Equity Research
Veeva (VEEV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Neogen Stock Tumbles on Q3 Earnings & Sales Miss, Margins Contract
by Zacks Equity Research
NEOG posts lower-than-expected earnings and revenues for the third quarter of fiscal 2025.
Walgreens Beats on Q2 Earnings, Withdraws Fiscal 2025 View, Stock Down
by Zacks Equity Research
WBA delivers better-than-expected earnings and revenues in the second quarter of fiscal 2025.
Is WisdomTree Cloud Computing ETF (WCLD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for WCLD
Veeva Systems (VEEV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Veeva Systems (VEEV) closed at $214.74, marking a +0.5% move from the previous day.
The First Q1 Earnings Land: Global Week Ahead
by John Blank
Global investors have yearned for clarity over President Trump's tariffs. But now they have it, and don't much like what they see.
Why Is Veeva (VEEV) Down 6.2% Since Last Earnings Report?
by Zacks Equity Research
Veeva (VEEV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
New Strong Buy Stocks for April 3rd
by Zacks Equity Research
NATL, BGC, NPSNY, ALX and VEEV have been added to the Zacks Rank #1 (Strong Buy) List on April 3, 2025.
Best Momentum Stocks to Buy for April 3rd
by Zacks Equity Research
VEEV, BNPQY and NECB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 3, 2025.
VEEV Stock Slips Despite New Research Site Clinical Trial System
by Zacks Equity Research
Veeva introduces a Research Site Clinical Trial Management System to streamline trial operations, enhance collaboration, and accelerate clinical research efficiency.
Wall Street Analysts Think Veeva (VEEV) Is a Good Investment: Is It?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Veeva (VEEV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Veeva (VEEV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
5 Momentum Stocks to Buy for April Despite a Disappointing March
by Nalak Das
Five stocks have strong momentum for April. These are: APP, MRVL, DOCS, RDDT, VEEV.
Top Stock Picks for Week of March 31, 2025
by Panel Of Zacks Experts
A medical info systems stock with a positive earnings ESP and a civil engineering company with upbeat estimate changes.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Here's How Much a $1000 Investment in Veeva Systems Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Should You Invest in the WisdomTree Cloud Computing ETF (WCLD)?
by Zacks Equity Research
Sector ETF report for WCLD
Veeva Systems Inc. (VEEV) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Veeva (VEEV) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Veeva (VEEV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Best Momentum Stock to Buy for March 17th
by Zacks Equity Research
PSO, VEEV and PAA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 17, 2025.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.